title: Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: a randomized intervention study.
abstract: The aim was to examine the feasibility and efficacy of a multifactorial risk factor intervention program in hypertensive patients at high cardiovascular risk. Treated hypertensive men, aged 50 to 72 years, with at least one of the following: serum cholesterol concentration > or = 6.5 mmol/L, diabetes mellitus, or smoking were randomized to multifactorial risk factor intervention (n = 253) or usual care (n = 255). The specific intervention was based on group meetings to encourage a lipid lowering diet and smoking cessation. Cholestyramine, nicotinic acid, fibrates, and later statins were used either as single drug therapy or in combination, following agreed guidelines in patients in whom the nonpharmacological intervention was judged to be insufficient. Usual care was given according to clinical practice. The median follow-up time was 6.6 years. Sixty-four patients (25.1%) died in the usual care group, compared with 41 patients (16.2%) in the intervention group (P = .016; 95% confidence interval, relative risk 0.42 to 0.92). The overall risk for fatal and nonfatal cardiovascular events was 29% lower in the intervention group than in the usual care group (P = .041). Relative to usual care, the intervention program lowered mean in-trial serum concentrations of total cholesterol (6.3%, P < .0001), LDL cholesterol (9.1%, P < .0001), and blood glucose (0.2 mmol/L, P < .05). Among smokers, at entry, cotinine-adjusted quit rates were 28% in the intervention group and 11% in the usual care group (P = .012) after 3 years. This study illustrates the very high cardiovascular risk in hypertensive patients 50 to 72 years of age with additional risk factors. The results indicate, however, that the gloomy prognosis may be improved by a dedicated risk factor intervention program.
authors.affiliation: Department of Medicine, Sahlgrenska University Hospital, Göteborg University, Gothenburg, Sweden. bjorn.fagerberg@medfak.gu.se
authors.forename: B
authors.initials: B
authors.lastname: Fagerberg
authors.forename: J
authors.initials: J
authors.lastname: Wikstrand
authors.forename: G
authors.initials: G
authors.lastname: Berglund
authors.forename: O
authors.initials: O
authors.lastname: Samuelsson
authors.forename: S
authors.initials: S
authors.lastname: Agewall
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality; D002784:Cholesterol / Q000097:blood; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000628:therapy; D005240:Feasibility Studies; D006439:Hemodynamics; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000178:diet therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000401:mortality* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000401:mortality / Q000628:therapy
chemical_list: D000959:Antihypertensive Agents; D002784:Cholesterol